Neratinib, a pan ERBB/HER inhibitor, restores sensitivity of PTEN-null, BRAFV600E melanoma to BRAF/MEK inhibition

IntroductionApproximately 50% of melanomas harbor an activating BRAFV600E mutation. Standard of care involves a combination of inhibitors targeting mutant BRAF and MEK1/2, the substrate for BRAF in the MAPK pathway. PTEN loss-of-function mutations occur in ~40% of BRAFV600E melanomas, resulting in i...

Descripción completa

Detalles Bibliográficos

Autores principales:	Evan DuBose, Samantha M. Bevill, Dana K. Mitchell, Noah Sciaky, Brian T. Golitz, Shelley A. H. Dixon, Steven D. Rhodes, James E. Bear, Gary L. Johnson, Steven P. Angus
Formato:	Artigo
Lenguaje:	Inglês
Publicado:	Frontiers Media S.A. 2024-05-01
Colección:	Frontiers in Oncology
Materias:	melanoma kinase inhibitor drug synergy ERBB3 resistance
Acceso en línea:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1191217/full
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!